Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CollPlant Biotechnologies Ltd (CLGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 6-K Quarterly results
08/24/2023 6-K Quarterly results
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million ● Received in July 2023, $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in accordance with the strategic collaboration agreement ● Entered into collaboration with Stratasys, a world-leading 3D printing company, with initial focus on the development of a bioprinting solution for the fabrication of CollPlant’ s regenerative breast implants ● Readying breast implant study in large animals for initiation by year end ● Continued positive sales trajectory for 3D bioinks ● Cash and cash equivalents totaled $22.3 million as of June 30, 2023; cash runway extended with addition...",
"COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023",
"OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2023"
07/24/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
07/18/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER"
06/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Notice and Proxy Statement with respect to the Company’ s Annual and Extraordinary General Meeting of Shareholders",
"Proxy Card for holders of ordinary shares with respect to the Company’ s Annual and Extraordinary General Meeting of Shareholders"
05/24/2023 6-K Quarterly results
Docs: "CURRENT REPORT",
"CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update ● Strong positive sales trajectory for rhCollagen based products ● Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant’ s recombinant human Collagen ● Readying sites to begin large-animal study planned in the second half of 2023 to advance 3D bioprinted regenerative breast implant program ● Conference call to be held on May 24, 2023 at 10:00 am U.S. ET; Dial-in information herein Rehovot, Israel, May 24, 2023 – CollPlant Biotechnologies , a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue rege..."
04/18/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
04/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs"
03/29/2023 6-K Quarterly results
03/29/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/30/2023 SC 13G/A INVESTMENT MANAGEMENT OF VIRGINIA LLC reports a 4.9% stake in COLLPLANT BIOTECHNOLOGIES LTD.
01/25/2023 SC 13G/A Loewenbaum Lilian S. reports a 8% stake in CollPlant Biotechnologies Ltd.
01/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Strategy"
01/13/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/11/2023 SC 13G/A MEITAV DASH INVESTMENTS LTD reports a 5.5% stake in CollPlant Biotechnologies Ltd
01/06/2023 DEL AM Form DEL AM - Delaying amendment:
01/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives"
01/03/2023 6-K Quarterly results
12/30/2022 F-3 Form F-3 - Registration statement by foreign private issuers:
12/01/2022 6-K Quarterly results
11/17/2022 6-K Quarterly results
11/15/2022 6-K Quarterly results
11/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"About CollPlant"
08/26/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CORPORATE PRESENTATION"
08/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results · Co-development of rhCollagen-based dermal and soft tissue fillers with AbbVie is progressing · Company’ s 3D bioprinted regenerative breast implant program remains on track to conclude large animal study in Q4 · Development of aseptic process for the production of sterile rhCollagen anticipated to be completed in Q4 · Strong balance sheet with cash and cash equivalents of $36M as of June 30, 2022 Rehovot, Israel August 25, 2022 -- CollPlant Biotechnologies , a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the second ...",
"COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022",
"OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2022"
06/29/2022 6-K Quarterly results
05/26/2022 6-K Quarterly results
05/02/2022 6-K Quarterly results
04/14/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"CORPORATE PRESENTATION"
03/25/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"Notice and Proxy Statement with respect to the Company’ s Annual and Extraordinary General Meeting of Shareholders",
"Proxy Card for holders of ordinary shares with respect to the Company’ s Annual and Extraordinary General Meeting of Shareholders"
03/24/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/24/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF THE FOREIGN PRIVATE ISSUER",
"CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy